



OLLSCOIL NA GAILLIMHE
UNIVERSITY OF GALWAY

Lunch-time seminar

From bench to bedside: translational research and clinical trials in redox research.

The Institute of Clinical Trials, University of Galway, is dedicated to bridging the gap between research and real-world healthcare applications. The focus on developing and translating ensures that discoveries made in clinical trials are efficiently transformed into practical solutions that improve patient care and healthcare delivery. From early-stage research to clinical trials, the Institute works to ensure that innovations are developed, tested, and translated into healthcare systems with maximum impact.

Speakers:

Motohiro Nishida, Professor at the Kyushu University: Fukuoka, Japan, studies the intracellular signaling pathways regulating adaptation or maladaptation of the heart against physical stresses. His interests include regulation of cardiac redox homeostasis by reactive sulfur species and pathophysiological roles of receptor-activated TRPC channels. He will present his work on *Supersulfide metabolism in cardiac stress resistance*.

Judy de Haan is a Baker Institute Fellow and Head of the Cardiovascular Inflammation and Redox Biology laboratory at the Baker Heart and Diabetes Institute. Prof de Haan's research focuses on improving the lives of diabetic patients by reducing the burden of cardiovascular complications. Her focus on the pathogenesis of oxidant stress has led to significant discoveries on the role of endogenous antioxidant enzyme defences. Her research focuses on the Nrf2/NLRP3-inflammasome axis. Her preclinical investigations hold tremendous potential for translation into humans. Prof. de Haan will discuss *Targeting the inflammatory Gasdermin-D pore improves cardiac ischemia reperfusion injury in mice*.

Prof. Sharon Glynn, Fulbright Scholar and Professor in Pathology at University of Galway, will discuss her research dedicated to developing a new set of therapeutics for the treatment of Triple Negative Breast Cancer (TNBC), which affects about 10-15% of women diagnosed with breast cancer. She will present her work: *Inducible nitric oxide synthase (iNOS) modulates tumour progression and immune responses leading to poor patient outcome in hormone receptor negative breast cancer*

Prof. Andrew Smyth, Professor of Clinical Epidemiology at University of Galway and a Consultant Nephrologist at Galway University Hospitals. His research interests are in the epidemiology of chronic kidney disease, particularly modifiable risk factors for chronic kidney disease and the relationship between diet and health outcomes. He was the first Irish-based recipient of a Wellcome Trust Clinical Research Career Development Fellowship and collaborates closely with the Population Health Research Institute (PHRI) of McMaster University. He will discuss higher potassium intake - and how it's linked with health, cognitive and physical function, and mortality. He will discuss *Findings from the INTERSTROKE Study*